Aquestive Therapeutics reports Q2 EPS (3c), consensus (12c)

Reports Q2 revenue $20.1M, consensus $12.38M. The company finished Q2 with cash and cash equivalents of approximately $90M and reaffirms its cash runway into 2026. The company said, “We have utilized this technology platform to drive the development of our product candidate Anaphylm(TM) as the first and only oral epinephrine product for the treatment of severe allergic reactions, including anaphylaxis. On a global basis, we believe Anaphylm has the potential to be a billion-dollar commercial opportunity. We also believe that our epinephrine prodrug platform branded as Adrenaverse(TM) is leading the way for potential multiple epinephrine prodrug pipeline opportunities that could produce another billion dollars in opportunities, if new product candidates developed by the Company are approved by the FDA. These opportunities, along with Libervant and our base business, have positioned the Company for continued growth over the next several years.”